A Pathologist's Perspective on Emerging Genomic Tests for Breast Cancer

Seminars in Oncology

Volumn 34, Issue SUPPL. 3, 2007, Pages

  Symmans, W Fraser ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

ARTICLE; BIOTECHNOLOGY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL DECISION MAKING; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENOME ANALYSIS; HORMONAL THERAPY; HUMAN; PRIORITY JOURNAL; PROGNOSIS;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; MASS SCREENING; PROGNOSIS; SPECIMEN HANDLING; TUMOR MARKERS, BIOLOGICAL;

EID: 34248512215     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2007.03.016     Document Type: Article

References (53)

1. Eifel P., Axelson J.A., Costa J., et al. National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 93 (2001) 979-989
2. Goldhirsch A., Wood W.C., Gelber R.D., et al. Meeting highlights: Updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21 (2003) 3357-3365
3. Kiang D.T., Frenning D.H., Goldman A.I., et al. Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer. N Engl J Med 299 (1978) 1330-1334
4. Klijanienko J., Laine-Bidron C., Vielh P., et al. Immunoenzymatic (EIA) assays of estrogen and progesterone receptors in fine-needle and surgical samples in breast cancer patients. Am J Clin Pathol 104 (1995) 289-293
5. Pertschuk L.P., Eisenberg K.B., Carter A.C., et al. Immunohistologic localization of estrogen receptors in breast cancer with monoclonal antibodies. Correlation with biochemistry and clinical endocrine response. Cancer 55 (1985) 1513-1518
6. De Rosa C.M., Ozzello L., Greene G.L., et al. Immunostaining of estrogen receptor in paraffin sections of breast carcinomas using monoclonal antibody D75P3 gamma: Effects of fixation. Am J Surg Pathol 11 (1987) 943-950
7. Goulding H., Pinder S., Cannon P., et al. A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples. Hum Pathol 26 (1995) 291-294
8. Alberts S.R., Ingle J.N., Roche P.R., et al. Comparison of estrogen receptor determinations by a biochemical ligand-binding assay and immunohistochemical staining with monoclonal antibody ER1D5 in females with lymph node positive breast carcinoma entered on two prospective clinical trials. Cancer 78 (1996) 764-772
9. Pertschuk L.P., Feldman J.G., Kim Y.D., et al. Estrogen receptor immunocytochemistry in paraffin embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222Sp gamma in frozen sections or cytosol-based ligand-binding assays. Cancer 77 (1996) 2514-2519
10. Harvey J.M., Clark G.M., Osborne C.K., et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17 (1999) 1474-1481
11. US Food and Drug Administration. Medical devices; classification/reclassification of immunohistochemistry reagents and kits-FDA. Final rule. Federal Register 63 (1998) 30132-30142
12. Taylor C.W. FDA issues final rule for classification and reclassification of immunochemistry reagents and kits. Am J Clin Pathol 111 (1999) 443-444
13. Rhodes A., Jasani B., Barnes D.M., et al. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: Interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 53 (2000) 125-130
14. Regitnig P., Reiner A., Dinges H.P., et al. Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories. Virchows Arch 441 (2002) 328-334
15. Gancberg D., Jarvinen T., di Leo A., et al. Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: An interlaboratory study assessing the reproducibility of HER-2/NEU testing. Breast Cancer Res Treat 74 (2002) 113-120
16. Mass R.D., Press M.F., Anderson S., et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 6 (2005) 240-246
17. Perez E.A., Suman V.J., Davidson N.E., et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 24 (2006) 3032-3038
18. Press M.F., Hung G., Godolphin W., et al. Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 54 (1994) 2771-2777
19. Schnitt S.J., and Jacobs T.W. Current status of HER2 testing: caught between a rock and a hard place. Am J Clin Pathol 116 (2001) 806-810
20. Hayes D.F., and Thor A.D. c-erbB-2 in breast cancer: development of a clinically useful marker. Semin Oncol 29 (2002) 231-245
21. Paik S., Bryant J., Tan-Chiu E., et al. Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 94 (2002) 852-854
22. Roche P.C., Suman V.J., Jenkins R.B., et al. Concordance between local and central laboratory HER2 testing in the Breast Intergroup trial N9831. J Natl Cancer Inst 94 (2002) 855-857
23. Simon R. Development and validation of therapeutically relevant multi-gene biomarker classifiers. J Natl Cancer Inst 97 (2005) 866-867
24. Ransohoff D.F. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 4 (2004) 309-314
25. Ransohoff D.F. Opinion: Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer 5 (2005) 142-149
26. Perou C.M., Jeffrey S.S., van de Rijn M., et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A 96 (1999) 9212-9217
27. Perou C.M., Sorlie T., Elsen M.B., et al. Molecular portraits of human breast tumours. Nature 406 (2000) 747-752
28. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351 (2004) 2817-2826
29. Habel L.A., Shak S., Jacobs M.K., et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 8 (2006) R25. http://breast-cancer-research.com/content/8/3/R25 [Epub]. Available at http://breast-cancer-research.com/content/8/3/R25.
30. Esteva F.J., Sahin A.A., Cristofanilli M., et al. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res 11 (2005) 3315-3319
31. Paik S., Shak S., Tang G., et al. Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer. [abstr 510]. Proc Am Soc Clin Oncol 23 (2005) 6S
32. van 't Veer L.J., Dai H., van de Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002) 530-536
33. van de Vijver M.J., He Y.D., van't Veer L.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347 (2002) 1999-2009
34. Wang Y., Klijn J.G., Zhang Y., et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365 (2005) 671-679
35. Foekens J.A., Atkins D., Zhang Y., et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 24 (2006) 1665-1671
36. Sotiriou C., Wirapati P., Loi S., et al. Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98 (2006) 262-272
37. Sotiriou C., Wiripati P., Loi S., et al. Better characterization of estrogen receptor (ER) positive luminal subtypes using genomic grade. [abstr]. Br Cancer Res Treat 94 (2005) S19
38. Fan C., Oh D.S., Wessels L., et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 355 (2006) 560-569
39. Symmans W.F., Ayers M., Clark E.A., et al. Total RNA yield and microarray gene expression profiles from fine needle aspiration and core needle biopsy samples of breast cancer. Cancer 97 (2003) 2960-2971
40. Ayers M., Symmans W.F., Stec J., et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22 (2004) 2284-2293
41. Hess K.R., Anderson K., Symmans W.F., et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24 (2006) 4236-4244
42. Ma X.J., Wang Z., Ryan P.D., et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5 (2004) 607-616
43. Goetz M.P., Suman V.J., Ingle J.N., et al. A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin Cancer Res 12 (2006) 2080-2087
44. Symmans W.F. Genomic testing for sensitivity of breast cancer to hormonal therapy. Clin Cancer Res 12 (2006) 1954-1955
45. Shi L., Reid L.H., Jones W.D., et al. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol 24 (2006) 1151-1161
46. Patterson T.A., Lobenhofer E.K., Fulmer-Smentek S.B., et al. Performance comparison of one-color and two-color platforms within the Microarray Quality Control (MAQC) project. Nat Biotechnol 24 (2006) 1140-1150
47. Tong W., Lucas A.B., Shippy R., et al. Evaluation of external RNA controls for the assessment of microarray performance. Nat Biotechnol 24 (2006) 1132-1139
48. Shippy R., Fulmer-Smentek S., Jensen R.V., et al. Using RNA sample titrations to assess microarray platform performance and normalization techniques. Nat Biotechnol 24 (2006) 1123-1131
49. Canales R.D., Luo Y., Willey J.C., et al. Evaluation of DNA microarray results with quantitative gene expression platforms. Nat Biotechnol 24 (2006) 1115-1122
50. Ji H., and Davis R.W. Data quality in genomics and microarrays. Nat Biotechnol 24 (2006) 1112-1113
51. Frueh F.W. Impact of microarray data quality on genomic data submissions to the FDA. Nat Biotechnol 24 (2006) 1105-1107
52. Casciano D.A., and Woodcock J. Empowering microarrays in the regulatory setting. Nat Biotechnol 24 (2006) 1103
53. Hudson K.L., Murphy J.A., Kaufman D.J., et al. Oversight of US genetic testing laboratories. Nat Biotechnol 24 (2006) 1083-1090